Literature DB >> 12893984

Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups.

Su-Jun Lee1, Khawja A Usmani, Brian Chanas, Burhan Ghanayem, Tina Xi, Ernest Hodgson, Harvey W Mohrenweiser, Joyce A Goldstein.   

Abstract

OBJECTIVES: Genetic polymorphisms of cytochromes P450 (CYPs) are a principal reason for inter-individual variations in the metabolism of therapeutic drugs and environmental chemicals in humans. The present study identifies 34 single nucleotide polymorphisms (SNPs) of CYP3A5 including 27 previously unidentified SNPs by direct sequencing of the exons, intron-exon junctions and 5'-upstream region of CYP3A5 from 92 racially diverse individuals (24 Caucasians, 24 Africans, 24 Asians, and 20 individuals of unknown racial origin).
RESULTS: Four new CYP3A5 SNPs produced coding changes: R28C, L82R, A337T, and F446S. CYP3A5 R28C occurred in African populations (allelic frequency of 4%). CYP3A5 A337T occurred in Asians (2% allelic frequency), CYP3A5 L82R (occurred in the racially unidentified group) and CYP3A5 F446S (identified in Caucasians with a 2% allelic frequency) were on an allele containing the splice change g.6986A>G known as CYP3A5*3. The newly identified allelic proteins were constructed by site-directed mutagenesis, expressed in Escherichia coli and purified. CYP3A5 L82R was expressed only as denatured CYP420, suggesting it may be unstable. CYP3A5*1 exhibited the highest maximal clearance for testosterone followed by CYP3A5 A337T > CYP3A5 R28C >> CYP3A5 F446S. CYP3A5*1 exhibited a higher V(max) for nifedipine oxidation than CYP3A5 A337T > CYP3A5 R28C >> CYP3A5 F446S. CYP3A5 A337T and CYP3A5 R28C exhibited a 42-64% lower V(max) for nifedipine oxidation than CYP3A5*1. CYP3A5 F446S exhibited a > 95% decrease in the intrinsic clearance for both 6beta-hydroxytestosterone and nifedipine oxidation.
CONCLUSION: This study identifies four new potentially defective coding alleles. CYP3A5 F446S is predicted to be more catalytically defective than the splice change alone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12893984     DOI: 10.1097/00008571-200308000-00004

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  40 in total

1.  PharmGKB summary: very important pharmacogene information for CYP3A5.

Authors:  Jatinder Lamba; Joan M Hebert; Erin G Schuetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2012-07       Impact factor: 2.089

2.  Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.

Authors:  Jaekyu Shin; Daniel F Pauly; Michael A Pacanowski; Taimour Langaee; Reginald F Frye; Julie A Johnson
Journal:  Pharmacotherapy       Date:  2011-10       Impact factor: 4.705

3.  Analysis of genetic variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 genes using oligonucleotide microarray.

Authors:  Yuanyuan Dong; Huasheng Xiao; Qi Wang; Chunxiu Zhang; Xiuming Liu; Na Yao; Haihui Sheng; Haiyan Li
Journal:  Int J Clin Exp Med       Date:  2015-10-15

4.  Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.

Authors:  Su-Jun Lee; William J Jusko; Christine G Salaita; Karim A Calis; Michael W Jann; Vicky E Spratlin; Joyce A Goldstein; Yuen Yi Hon
Journal:  J Clin Pharmacol       Date:  2006-05       Impact factor: 3.126

5.  Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism.

Authors:  Jacques Turgeon; Chantal Pharand; Véronique Michaud
Journal:  CMAJ       Date:  2006-06-06       Impact factor: 8.262

6.  The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population.

Authors:  Ya-Huei Liou; Chien-Ting Lin; Ying-Jye Wu; Lawrence Shih-Hsin Wu
Journal:  J Hum Genet       Date:  2006-08-19       Impact factor: 3.172

7.  A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system.

Authors:  Su-Jun Lee; Ilse P van der Heiden; Joyce A Goldstein; Ron H N van Schaik
Journal:  Drug Metab Dispos       Date:  2006-10-11       Impact factor: 3.922

8.  Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

Authors:  Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

9.  Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent.

Authors:  F Aminkeng; C J D Ross; S R Rassekh; L R Brunham; J Sistonen; M-P Dube; M Ibrahim; T B Nyambo; S A Omar; A Froment; J-M Bodo; S Tishkoff; B C Carleton; M R Hayden
Journal:  Pharmacogenomics J       Date:  2013-04-16       Impact factor: 3.550

10.  CYP3A5*3 polymorphism and cancer risk: a meta-analysis and meta-regression.

Authors:  Bao-Sheng Wang; Zhen Liu; Wei-Xue Xu; Shao-Long Sun
Journal:  Tumour Biol       Date:  2013-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.